Themis Medicare Ltd logo

Themis Medicare Ltd

NSE: THEMISMED BSE: 530199

₹100.90

-1.16 (1.14%)

Sun, 22 Nov 2026, 05:21 pm

mtf coin illustrationMTF 5xInvest in Themis Medicare Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)934.82
PE Ratio23.28
Dividend0.49
Health TechnologyHealth Technology
Pharmaceuticals: MajorPharmaceuticals: Major
24.5K24.5K

Themis Medicare Analysis

dividend

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (15.4x coverage).
thumbs up icon

Cons

  • Dividends per share have fallen over the past 10 years.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Themis Medicare's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Themis Medicare's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

thumbs up icon

Pros

  • Themis Medicare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Themis Medicare is profitable, therefore cash runway is not a concern.
  • Themis Medicare is profitable, therefore cash runway is not a concern.
  • Debt is covered by short term assets, assets are 2x debt.
  • Themis Medicare's cash and other short term assets cover its long term commitments.
  • The level of debt compared to net worth has been reduced over the past 5 years (236.8% vs 48.2% today).
thumbs up icon

Cons

  • Debt is not well covered by operating cash flow (0.4%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2.1x annual interest expense, ideally 3x coverage).
  • Themis Medicare's level of debt (48.2%) compared to net worth is high (greater than 40%).
  • High level of physical assets or inventory.

management

thumbs up icon

Pros

  • The average tenure for the Themis Medicare board of directors is over 10 years, this suggests they are a seasoned and experienced board.
  • Sachin's compensation has increased in line with Themis Medicare recently becoming profitable.
  • The tenure for the Themis Medicare management team is about average.
thumbs up icon

Cons

  • Sachin's remuneration is higher than average for companies of similar size in India.

misc

thumbs up icon

Pros

    thumbs up icon

    Cons

    • Themis Medicare is not covered by any analysts.

    past

    thumbs up icon

    Pros

    • Themis Medicare used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
    thumbs up icon

    Cons

    • Themis Medicare has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
    • Themis Medicare's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
    • Themis Medicare's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
    • Themis Medicare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
    • Themis Medicare has become profitable in the last year making it difficult to compare the IN Pharmaceuticals industry average.

    value

    thumbs up icon

    Pros

    • Themis Medicare is good value based on assets compared to the IN Pharmaceuticals industry average.
    • Themis Medicare is good value based on earnings compared to the IN Pharmaceuticals industry average.
    • THEMISMED outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
    • THEMISMED outperformed the Market in India which returned -14.5% over the past year.
    thumbs up icon

    Cons

    • Themis Medicare's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
    • Themis Medicare's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
    • Themis Medicare is overvalued based on earnings compared to the India market.
    • NSEI:THEMISMED is down -1.7% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
    • NSEI:THEMISMED is down -1.7% underperforming the market in India which returned 8% over the past month.
    pocketful logo lightpocketful logo dark
    PricingBecome a Partner
    search icon
    /

    No results for ''

    Popular search

    • popular search iconSuzlon Energy Ltd
    • popular search iconIndian Railway Finance Corporation Ltd
    • popular search iconTata Motors Ltd
    • popular search iconTata Steel Ltd
    • popular search iconRail Vikas Nigam Ltd

    Recent search

        Log In
        search icon

        No results for ‘’

          Popular search

          • popular search iconSuzlon Energy Ltd
          • popular search iconIndian Railway Finance Corporation Ltd
          • popular search iconTata Motors Ltd
          • popular search iconTata Steel Ltd
          • popular search iconRail Vikas Nigam Ltd
          • popular search iconReliance Industries Ltd
          pocketful logo lightpocketful logo dark
          • Pricing
          • Become a Partner
          Log In
          • home icon
          • arrow iconstocks
          • arrow iconthemis medicare ltd
          • arrow iconanalysis
          • Overview
          • Analysis
          • Financials
          • Ratios
          • shareholding
          • Technical Analysis
          • Corporate Actions
          • Peer Comparison
          • About
          • Company History
          • Deals
          • News
          • FAQs

          Open Your Free Demat Account Now!

          Step into a world of zero fees and limitless opportunities!

          pocketful logo
          • Quick Links

            • Open Demat Account
            • Pocketful Web
            • Pocketful App
            • Pricing
            • Authorised Person
            • Pocketful Calculators
            • Compliance Links
          • Pages

            • Tools
            • Blogs
            • ETF Screener
            • IPO
            • ETF
            • Bonds
            • Index Heat Map
          • Products

            • Stocks
            • Commodity
            • Subscription
            • Free Stock Screener
            • Pocketful GPT
            • MTF
            • Mutual Funds
          • Company

            • About us
            • Contact us
            • Terms and Conditions
            • Policies & Procedures
            • Privacy Policy
            • Disclosure
            • Careers
          • Socials

            • Facebook iconFacebook
            • Twitter iconTwitter
            • Instagram iconInstagram
            • LinkedIn iconLinkedIn
            • Youtube iconYoutube

          2022-25 Pocketful. All rights reserved, Built with in India

          Version -5.76

          app image 1app image 2

          Stocks:

          AllABCDEFGHIJKLMNOPQRSTUVWXYZ

          Explore

          Calculators
          Popular Calculators
          Group Stocks
          Asset Management Companies
          Popular Stocks
          Indian Indices
          Sector Wise Stocks
          IPO
          Share Market
          Best MF Schemes
          Platforms
          Resources
          Gold Rates in Top Cities
          Silver Rates in Top Cities

          Others:

          NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

          Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800